Gilteritinib Enhances Graft-versus-Leukemia Effects against FLT3-ITD Mutant Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

0
47
Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3 internal tandem duplication mutant transfected Ba/F3 leukemia in mice.
[Bone Marrow Transplantation]
Abstract